PhD, Dr., Doctoral Supervisor, Chief Physician, Adjunct PI of the Institute of Medical Genetics, Fudan University. MD, Postdoctoral Fellow
Affiliated HospitalHuashan Hospital Affiliated to Fudan University
→
Deputy Director of the Department of Neurology, Huashan Hospital Affiliated to Fudan University; Executive Deputy Director of the Institute of Neurology, Fudan University. Recipient of the Ministry of Education's 2018 "Changjiang Scholars Program" Young Scholar Award, Fudan University's "Excellent 2025" Talent Cultivation Program Outstanding Talent Award, and Fudan University's "Key Position" Dr.. New Cornerstone Researcher, Xianghui Scholar, recipient of the 4th National Innovation and Pioneering Medal. Standing Committee Member and Vice Chairman of the Youth Committee of the Chinese Medical Association Neurology Branch, Chief Scientist of the National Science and Technology Innovation 2030 "Brain Science and Brain-like" Dementia Major Project, Vice President of the Alzheimer's Disease Prevention and Treatment Association. Selected as one of the 6th National Renowned Doctors. Specializes in memory decline, brain atrophy, gait instability, dementia (Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson's dementia, rapidly progressive dementia, etc.), Parkinson's syndrome, etc. The institute has accumulated over 5,000 outpatient visits annually, established a specialized ward for cognitive impairment, mapped modifiable risk factors for Alzheimer's disease (AD), and spearheaded the development of international evidence-based prevention guidelines for AD, which have been adopted by the WHO, the United States, and other organizations in formulating AD prevention strategies. It innovatively mapped the plasma proteome of human health and disease, achieving early prediction of AD with a single drop of blood (diagnostic accuracy of 92.3%); developed early AD screening technology, discovering new markers such as YWHAG in cerebrospinal fluid; and revealed the AD treatment targets TREM1, TREM2, and MS4A6A. This achievement won the first prize of the 2025 Shanghai Science and Technology Progress Award. The institute was the first author of the 2025 Shanghai Science and Technology Progress Award. It also discovered the novel therapeutic target FAM171A2 for Parkinson's disease for the first time globally. Furthermore, it constructed a new research paradigm of "artificial intelligence + biomedical big data + multidisciplinary integration," publishing a series of significant findings in top international journals such as Science and Cell. He was selected as one of the most cited Chinese researchers in the field of neuroscience in 2019 and ranked 24th in the international ranking of "Global Dementia Experts" published by the renowned European institution Expertscape.